Sensitive detection of Nampt(PBEF/Visfatin)in human serum for point-of-care applications using aptamer based capacitive biosensor

Warning The system is temporarily closed to updates for reporting purpose.

Kolkar Mohammed, Javed Hussain Niazi and Park, Jee-Wong and Kallempudi, Sreenivasa Saravan and Qureshi, Anjum and Gürbüz, Yaşar and Gu, Man Bock (2012) Sensitive detection of Nampt(PBEF/Visfatin)in human serum for point-of-care applications using aptamer based capacitive biosensor. In: IEEE EMBS Special Topic Conference on Point-of-Care Healthcare Technologies, Bangalore, India. (Accepted/In Press)

[img]PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader


NAMPT is a multifunctional protein, also known as visfatin or pre-B cell colony-enhancing factor, which exists as the rate-limiting intracellular enzyme for nicotinamide adenine dinucleotide (NAD) synthesis starting from nicotinamide [1]. The plasma Nampt levels are reported to have correlation with obesity and obese related metabolic disease, such as Type 2 diabetes mellitus (T2DM), cardiovascular diseases [2] and hyperlipidemia [3] due to association with lipoprotein and cholesterol. Therefore, sensitive detection of Nampt potentially enable accurate diagnosis of T2DM, cardiovascular and hyperlipidemia diseases. In this study, for the first time, we developed an ssDNA aptamer that specifically bind Nampt (Kd=72.52 nM) in human serum by systematic evolution of ligands by exponential enrichment (SELEX) process. Nampt-specific ssDNA aptamers were then applied as the recognition molecules for the development of a capacitive biosensor using non-Faradaic impedance spectroscopy (nFIES), which converts the biological binding event into a quantifiable signal for sensitive and efficient detection of the Nampt (Fig. 1). The interaction of aptamer-Nampt induced the change in dielectric properties, charge distribution, and conductivity. The limit of detection was 1 ng/ml with a dynamic range of upto 50 ng/ml in serum and this range is under the clinical requirements both in the normal Nampt levels, which is 15.8 ng/ml, and in the T2DM patients level, which is 31.9 ng/ml. This assay system for Nampt detection using aptamers is a potential alternative approach for applications in clinical studies and Point-Of-Care health technologies.

Item Type:Papers in Conference Proceedings
Subjects:R Medicine > RZ Other systems of medicine
T Technology > TK Electrical engineering. Electronics Nuclear engineering
ID Code:20677
Deposited By:Javed Kolkar
Deposited On:04 Dec 2012 22:55
Last Modified:31 Jul 2019 15:47

Repository Staff Only: item control page